This study is being done to answer the following question:
Can a combination of 3 targeted drugs work together to lower the chance of lung cancer growing or spreading?
Researchers will test adding the drug ramucirumab to the combination of osimertinib and INC280 (capmatinib), which are drugs that are used to treat non-small cell lung cancer that has EGFR and MET gene changes.
We are doing this study because we want to find out if using the combination of drugs in Group 1 [INC280 (capmatinib), osimertinib, ramucirumab] is beneficial compared to using the combination of drugs in Group 2 [INC280 (capmatinib), osimertinib] for treating non-small cell lung cancer tumors that have EGFR and MET gene changes. The drug combinations in both of these groups are experimental and are not being compared to the usual approach to treating non-small cell lung cancer that has EGFR and MET gene changes. The usual approach is the care most people get for their cancer.